期刊
CANCERS
卷 15, 期 15, 页码 -出版社
MDPI
DOI: 10.3390/cancers15153880
关键词
biomarkers; early detection; hepatocellular cancer; biliary tract cancer
类别
Hepatocellular cancer and biliary tract cancers have poor prognosis, but early diagnosis can lead to curative treatment. This review discusses the recommended diagnostic tests for early detection and recent advancements in this field.
Simple Summary Hepatocellular cancer and biliary tract cancers are associated with poor prognosis, particularly in advanced stages. However, early diagnosis offers the potential for curative treatment. In this review, our objective was to compile the standard diagnostic tests recommended for early detection in individuals with specific risk factors, as well as to review the recent advancements in this field. Hepatocellular cancer (HCC) and biliary tract cancers (BTCs) have poor survival rates and a low likelihood of a cure, especially in advanced-stage disease. Early diagnosis is crucial and can significantly improve survival rates through curative treatment approaches. Current guidelines recommend abdominal ultrasonography (USG) and alpha-fetoprotein (AFP) monitoring for HCC screening in high-risk groups, and abdominal USG, magnetic resonance imaging (MRI), and magnetic resonance cholangiopancreatography (MRCP) monitoring for biliary tract cancer. However, despite this screening strategy, many high-risk individuals still develop advanced-stage HCC and BTC. Blood-based biomarkers are being developed for use in HCC or BTC high-risk groups. Studies on AFP, AFP-L3, des-gamma-carboxy prothrombin, glypican-3 (GPC3), osteopontin (OPN), midkine (MK), neopterin, squamous cell carcinoma antigen (SCCA), Mac-2-binding protein (M2BP), cyclic guanosine monophosphate (cGMP), and interleukin-6 biomarkers for HCC screening have shown promising results when evaluated individually or in combination. In the case of BTCs, the potential applications of circulating tumor DNA, circulating microRNA, and circulating tumor cells in diagnosis are also promising. These biomarkers have shown potential in detecting BTCs in early stages, which can significantly improve patient outcomes. Additionally, these biomarkers hold promise for monitoring disease progression and evaluating response to therapy in BTC patients. However, further research is necessary to fully understand the clinical utility of these biomarkers in the diagnosis and management of HCC and BTCs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据